BioNTech SE has finalised its acquisition of Biotheus, a clinical-stage biotechnology company focused on novel antibody development for oncology and inflammatory diseases. The transaction, initially announced in November 2024, enhances BioNTech’s research and development capabilities, particularly in bispecific antibodies. The
BioNTech, a next-generation immunotherapy company, and Autolus Therapeutics, a clinical-stage biopharmaceutical company, announced a strategic collaboration on February 8, 2024. The collaboration aims to advance both companies’ autologous CAR-T programs towards commercialisation, pending regulatory authorisations. The strategic alliance leverages manufacturing and
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
